No Detail Found!

Clinical efficacy and immunomodulatory mechanism of budesonide nasal spray combined with mucus promoter in patients with chronic sinusitis

Author(s)
Bo Luan Department of ENT, Zhejiang Xin'an International Hospital,Jiaxing 314001, Zhejiang Province,China
Dachen Huang Department of ENT, Zhejiang Jiaxing Wangdian People's Hospital,Jiaxing 314001, Zhejiang Province,China
Qi Shen Department of ENT, Zhejiang Xin'an International Hospital,Jiaxing 314001, Zhejiang Province,China
Xiaoyan Wang Department of ENT, Zhejiang Xin'an International Hospital,Jiaxing 314001, Zhejiang Province,China
Li Ling Department of ENT, Zhejiang Xin'an International Hospital,Jiaxing 314001, Zhejiang Province,China
Jufang Shen Department of ENT, Zhejiang Xin'an International Hospital,Jiaxing 314001, Zhejiang Province,China
Jin Fang Department of ENT, Zhejiang Xin'an International Hospital,Jiaxing 314001, Zhejiang Province,China
Kan Liu Department of ENT, Zhejiang Xin'an International Hospital,Jiaxing 314001, Zhejiang Province,China
Abstract
Chronic rhinosinusitis (CR) seriously affects the patient's life quality, and current clinical treatment faces certain challenges. This study observed the effects of budesonide nasal spray combined with mucus promoter on the clinical efficacy and immunomodulatory mechanism of CR patients. 105 patients with CR from Zhejiang Xin'an International Hospital between January 2021 and January 2024 were categorized into EL group and BE group, both groups underwent mucus promoter intervention and BE group were added with budesonide nasal spray intervention. Inflammatory and immunity indicators (CD4+ and CD8+ Tcells percentage) and clinical efficacy were mainly assessed. Secondary results included Lund-Kenndey score, Lund-Mackey score, nasal ventilation function [DCAN, NCV, NMCA, and nasal airway resistance], clinical symptom scores, adverse effects incidences, and recurrence rates. After treatment, the indicators of the both groups were superior to pre-treatment (P<0.05). The CD4+ Tcells percentage, CD4+/CD8+, NCV, NMCA, clinical symptom scores and clinical efficacy in BE group were markedly above the EL group, and inflammatory indicators, CD8+ Tcells percentage, Lund-Kenndey score, Lund-Mackey score, DCAN, nasal airway resistance, adverse effects incidences and recurrence rate were markedly below the EL group (P<0.05). This combined therapy has a remarkable curative effect, which is worthy of popularizing and use in the clinic.
Publication Details
Page(s) 759-769
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
chronic rhinosinusitis, immune indicator, mucus promoter, budesonide nasal spray, inflammatory indicator
References
Albu S .2020 .Chronic rhinosinusitis: An update on epidemiology, pathogenesis and management. J. Clin. Med, 9(7) : 2285.
Aljabr W,Al Amari A,Abbas B,Karkashan A,Alamri S,Alnamnakani M,Al Qahtani A .2022 .Evaluation of the levels of peripheral CD3, CD4 and CD8 T cells and IgG and IgM antibodies in COVID-19 patients at different stages of infection. , 10(1) : e00845-00821.
Bachert C,Marple B,Schlosser RJ,Hopkins C,Schleimer RP,Lambrecht BN,Bröker BM,Laidlaw T,Song WJ .2020 .Adult chronic rhinosinusitis. Nat. Rev. Dis. Primers., 6(1) : 86.
Bernstein JA,White AA,Han JK,Lang DM,Elkayam D,Baroody FM D .2023 .Review of evidence supporting the use of nasal corticosteroid irrigation for chronic rhinosinusitis. , 130(1) : 46-57.
Bleier BS,Paz Lansberg M BS .2021 .Acute and chronic sinusitis. Med, 105(5) : 859-870.
Cao P,Wang Z,Schleimer RP .2019 .Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes. , 122(1) : 33-40.
Cartagena MB,Acosta RM,Piñero AG,Ferrer MS,Díaz PG,Mezquida JR,Muñoz IP,Jover AS .2023 .P099 Effect of a mucolytic agent delivered through sinus pulsating aerosol system (SPAS) device on sinonasal symptoms and patient report outcomes in people with cystic fibrosis (PwCF). J. Cyst. Fibros., 22 : S94.
Chen H,Zhang L,Lou H,Wang Y,Cao F,Wang C .2021 .A randomized trial of comparing a combination of montelukast and budesonide with budesonide in allergic rhinitis. , 131(4) : E1054-E1061.
Cho SH,Hamilos DL,Han DH,Laidlaw TM .2020 .Phenotypes of chronic rhinosinusitis. J. Allergy Clin. Immunol, 8(5) : 1505-1511.
Ganji A,Farahani I,Khansarinejad B,Ghazavi A,Mosayebi G .2020 .Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol. Dis, 83 : 102437.
Hanson C and Lepule K .2021 .Management of acute and chronic sinusitis. S. Afr. Pharm. J., 88(5) : 22-28.
He B,Yang J,Dang L,Sun M,Liu J,Xin W .2024 .Eucalyptol, limonene and pinene enteric soft capsules relieve otitis media with effusion in mice based on AQP5-TLR4/MyD88/NF-κB pathway. Drug Eval. Res., 47(8) : 1820-1826.
Heo YA .2021 .Budesonide/glycopyrronium/formoterol: A review in COPD. , 81(12) : 1411-1422.
Hirsch AG,Nordberg C,Bandeen Roche K,Tan BK,Schleimer RP,Kern RC,Sundaresan A,Pinto JM,Kennedy TL,Greene JS .2020 .Radiologic sinus inflammation and symptoms of chronic rhinosinusitis in a population-based sample. , 75(4) : 911-920.
Kaliniak S,Fiedoruk K,Spałek J,Piktel E,Durnaś B,Góźdź S,Bucki R,Okła S R .2024 .Remodeling of paranasal sinuses mucosa functions in response to biofilm-induced inflammation. J. Inflamm. Res., 21 : 1295-1323.
Kanlioglu Kuman N,Kozaci LD,Sen S,Senturk E,Cokpinar S,Yaman E,Kilicaslan N,Karadag F .2021 .Prognostic significance of inflammatory markers IL-6, sP-selectin, TNF-α, BNP-32, and procalcitonin levels in thoracic surgery. Indian J. Surg., 83(3) : 740-748.
Kardos P,Dinh Q,Fuchs KH,Gillissen A,Klimek L,Koehler M,Sitter H,Worth H H .2020 .German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. Respir. Med, 170 : 105939.
Kato A,Schleimer RP,Bleier BS .2022 .Mechanisms and pathogenesis of chronic rhinosinusitis. J. Allergy Clin. Immunol, 149(5) : 1491-1503.
Kolkhir P,Akdis CA,Akdis M,Bachert C,Bieber T,Canonica GW,Guttman-Yassky E,Metz M,Mullol J,Palomares O,Renz H,Ständer S,Zuberbier T,Maurer M .2023 .Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat. Rev. Drug Discov, 22(9) : 743-767.
Kostić M,Ivanov M,Babić SS,Petrović J,Soković M,Ćirić A .2020 .An up-to-date review on bio-resource therapeutics effective against bacterial species frequently associated with chronic sinusitis and tonsillitis. Curr. Med, 27(41) : 6892-6909.
Lee HY,Pyo JS,Kim SJ .2021 .Distinct patterns of tissue remodeling and their prognostic role in chronic rhinosinusitis. ORL., 83(6) : 457-463.
Lin L,Lan J,Dai F,Wei J,Chen Z,Sun G .2020 .Efficacy of budesonide nasal spray on neutrophilic chronic rhinosinusitis with nasal polyps: a combined clinical and experimental study. Int. Arch. Allergy Immunol, 181(7) : 551-562.
Ma S,Lei X,Tu J,Tian C,Lian G,Li W,Wang D .2021 .Effect of glucocorticoids infiltration on CRSwNP after endoscopic sinus surgery and the curative efficacy of nasal ventilation function and mucociliary clearance. Am. J. Transl. Res., 13(4) : 3826.
Macias Valle L and Psaltis A .2021 .A scholarly review of the safety and efficacy of intranasal corticosteroids preparations in the treatment of chronic rhinosinusitis. Ear Nose Throat J., 100(5) : 295-301.
Mygind N,Nielsen LP,Hoffmann HJ,Shukla A,Blumberga G,Dahl R,Jacobi H R .2001 .Mode of action of intranasal corticosteroids. J. Allergy Clin. Immunol, 108(1) : S16-S25.
Patel GB,Kern RC,Bernstein JA,Hae Sim P,Peters AT .2020 .Current and future treatments of rhinitis and sinusitis. J. Allergy Clin. Immunol, 8(5) : 1522-1531.
Peric A,Soklic TK,Aleksic A,Kopacheva Barsova G,Peric AV G .2021 .Efficacy and safety of Myrtol® standardized in the treatment of acute and chronic rhinosinusitis: A review of literature. J. Clin. Pract. Res., 43(1) : 3.
Preethi A,Venkatraman R,Karthika U,Rangapriya A .2023 .Evaluation of the efficacy of magnesium sulfate in reducing blood loss in functional endoscopic sinus surgery: a randomized double-blinded controlled trial. Cureus., 15(5) : e38636.
Reichardt SD,Amouret A,Muzzi C,Vettorazzi S,Tuckermann JP,Lühder F,Reichardt HM,Comer BT,Hughes S,Ting JY,Higgins TS .2021 .Diagnostic criteria of recurrent acute rhinosinusitis: a systematic review. Am. J. Rhinol. Allergy., 35(3) : 383-390.
Shirindza N and Bronkhorst E,Shukla RH,Nemade SV,Shinde KJ .2020 .Comparison of visual analogue scale (VAS) and the nasal obstruction symptom evaluation (NOSE) score in evaluation of post septoplasty patients. WJOHNS., 6(1) : 53-58.
Taheri A,Shahzamani A,Asadi M .2024 .Diagnostic accuracy of sino-nasal outcome test-22 and LundKennedy endoscopic score for chronic rhinosinusitis in pre-bone marrow transplantation assessment. J. Res. Med. Sci., 29(1) : 67.
Tamene S,Dalhoff K,Schwarz P,Backer V,Aanaes K V .2023 .Systemic corticosteroids in treatment of chronic rhinosinusitis-a systematic review. Eur. Clin. Respir. J., 10(1) : 2240511.
Tsuda T,Takeda K,Terada R,Tanaka S,Waki S,Akama T,Nishimura H T .2024 .Osteitis in eosinophilic chronic rhinosinusitis. Ear Nose Throat J., 103(12) : NP741-NP748.
Wang H,Zuo Y,Li J,Wang W .2020 .Effects of glucocorticoid therapy on nasal conditions and inflammatory factors in patients with allergic rhinitis. Int. J. Clin. Exp. Med, 13(4) : 2154-2162.
Wijnants D,Stalmans I,Vandewalle E .2007 .The effects of intranasal, inhaled and systemic glucocorticoids on intraocular pressure: A literature review. J. Clin. Med, 11(7) : .
Zieglmayer P,Schmutz R,Lemell P,Unger Manhart N,Nakowitsch S,Goessl A,Savli M,Zieglmayer R,Prieschl‐Grassauer E .2020 .Fast effectiveness of a solubilized low‐dose budesonide nasal spray in allergic rhinitis. Clin. Exp, 50(9) : 1065-1077.
0

Citations

0

Downloads

104

Views